International HIV AIDS 2012 Conference TopicsNeuilly-sur-Seine, France, April 26, 2011 -- The main theme of the 2012 HIV AIDS ISHEID Conference has just been announced: 'From HIV Testing to Cure'. This biennial international AIDS conference will take place next time in Marseille, France, May 23-25, 2012.
“Despite major advances in the past 25 years, HIV infection remains a global threat with major scientific, societal and human challenges ahead”, declared Alain Lafeuillade, chair of the meeting. This 3-day International HIV conference will tackle the issues from virology to therapy, via social sciences and human rights.
HIV currently infects 33 million individuals worldwide and kills 2 million people annually. In the absence of a preventive vaccine, new prevention strategies have to be tested, such as pre-exposure prophylaxis. Consequently, HIV prevention will be the subject of an entire session of the conference.
Even if antiretroviral therapy provides better and longer lives to patients, the search for a cure remains the ultimate goal. The best experts in the field, like Tae-Wook Chun and Franck Maldarelli (Bethesda, USA) will present the most recent results in terms of HIV eradication trials.
Several sessions will also be dedicated to therapy management, including the pharmacological interactions with recently introduced new compounds against hepatitis C.
Finally, at a time when the financial crisis impacts health care systems, the meeting will also address the issues of cost-effectiveness, antiretroviral generics, and health coverage.
The HIV AIDS 2012 Conference will welcome key opinion leaders and participants from all around the world, including scientists, practitioners, and activists. It will take place at the Congress Center of Marseille, France.
About the conference:
The Steering Committee contains Professor Jean-François Delfraissy (Director of the French Agency of AIDS Research, Paris, France), Jose Gatell (Barcelona, Spain), Guido Poli (Milano, Italy), Jean-Pierre Routy (Montreal, Canada), Christine Rouzioux (Paris, France), Vicente Soriano (Madrid, Spain), Hans-Jürgen Stellbrink (Hambourg, Germany) and Stefano Vella (Rome, Italy). Website: http://www.isheid.com
Blvd Paul Emile Victor, 92523
Ph: +33 (0) 1 40 88 97 97
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release International HIV AIDS 2012 Conference Topics here
News-ID: 172575 • Views: 1316
More Releases from Overcome
International AIDS 2012 Conference Based on Excellence
The next AIDS ISHEID 2012 conference announced to be held in Marseilles, France, is a timely measure and is capable of bringing about a revolution. Neuilly-sur-Seine, FR, May 30, 2011 -- The Human Immunodeficiency Virus (HIV) has been ravaging the planet ever since it first infused itself into the body of the first human prey. Amongst the numerous efforts initiated towards fighting this deadly virus, ISHEID (International Symposium HIV & Emerging
HIV AIDS Biennial International Conference Ready For 2012
Neuilly-sur-Seine, France, May 06, 2011 -- The International Symposium of HIV and Emerging Infectious Diseases (ISHEID) Congress is announcing its HIV AIDS 2012 conference, to be held in Marseille, France from May 23 to May 25, 2012. This is an important conference -a "meeting of the minds" if you will- consisting of some of the top researchers and scientists in the field of HIV research and care. Abstracts will be
Monthly Leaders Interviews in Preparation of the HIV AIDS 2012 Conference
The next biennial ISHEID Conference will attract the world leading HIV AIDS experts in Marseille, France, May 23-25, 2012. The Steering Committee has just announced the conference theme: ‘From HIV Testing to HIV Cure’. Meanwhile, monthly interviews of international key opinion leaders will be published on the conference website at http://www.isheid.com/en/committees/interview.html Neuilly-sur-Seine, France, May 04, 2011 -- HIV currently infects 33 million individuals worldwide and kills 2 million people annually. In
More Releases for HIV
HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: email@example.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral